Inactive Instrument

Searle Co Ltd Stock Pakistan S.E.

Equities

Pharmaceuticals

End-of-day quote Pakistan S.E.
- PKR - Intraday chart for Searle Co Ltd

Financials

Sales 2024 * 44.08B 158M 217M Sales 2025 * 50.94B 183M 250M Capitalization 29.22B 105M 144M
Net income 2024 * 1.22B 4.38M 5.99M Net income 2025 * 2.88B 10.37M 14.18M EV / Sales 2024 * 1.18 x
Net Debt 2024 * 22.97B 82.59M 113M Net Debt 2025 * 22.21B 79.85M 109M EV / Sales 2025 * 1.01 x
P/E ratio 2024 *
22.1 x
P/E ratio 2025 *
10.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 59.07%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 07-12-31
Director of Finance/CFO - 14-10-22
Chief Tech/Sci/R&D Officer - 15-12-31
Members of the board TitleAgeSince
Chief Executive Officer - 07-12-31
Director/Board Member 60 -
Director/Board Member - 21-02-25
More insiders
The Searle Company Limited is a Pakistan-based company, which is engaged in the manufacture of pharmaceutical and other consumer products. The Company’s product categories include pharmaceutical, biopharmaceutical, nutraceutical, nutrition, consumer, and medical devices and disposables. The Company's product portfolio in the pharmaceutical range includes therapeutic areas, such as cardiovascular, respiratory care, gastroenterology, pain management, central nervous system (CNS), ortho care, neuropsychiatry, probiotics, antibiotics, and nutritional care. Its pharmaceutical products include Analgesic & Muscle-Relaxant, Anti-Allergy & Anti-Tussive, Anti-Anemic, Anti-Chelating, Anti-infective, Anti-Neoplastic, Anti-Thrombotic, Cardiovascular, Endocrinology & Metabolism. It also focuses on specialty generic branded portfolios and targeting differentiated products. Its subsidiaries include IBL HealthCare Limited, Searle Pharmaceuticals (Private) Limited, and others.
More about the company